Outcomes of frail patients undergoing high‐dose chemotherapy and autologous stem cell transplantation for multiple myeloma
In patients with multiple myeloma (MM) not-eligible for autologous haematopoietic cell transplantation (autoHCT), a simplified frailty index (SFI) identifies frail patients at risk for poor outcomes, but data are limited for transplant-eligible patients. In this registry-based retrospective study, we used an adapted version of the SFI to determine the prevalence of frailty in patients ≥65 years of age with MM undergoing autoHCT. Out of 5563 patients, 37.9% of patients were classified as frail and although they had increased non-relapse mortality (NRM) and inferior overall survival, the NRM at 100 days remained low (<2%) compared with non-frail patients.
Authors
- Mehdi Hamadani (ORCID: https://orcid.org/0000-0001-5372-510X)
- Ravi Kishore Narra (ORCID: https://orcid.org/0000-0002-1675-8479)
- Othman Salim Akhtar (ORCID: https://orcid.org/0000-0003-1673-9670)
- Anita D’Souza (ORCID: https://orcid.org/0000-0002-1092-5643)
- Meera Mohan (ORCID: https://orcid.org/0000-0002-6913-6526)
- Binod Dhakal (ORCID: https://orcid.org/0000-0002-4377-9742)
- Ciara L. Freeman (ORCID: https://orcid.org/0000-0002-0662-6480)
- Xi Fang
- Temitope Oloyede
- Marcelo C. Pasquini (ORCID: https://orcid.org/0000-0003-1579-2293)
- Soyoung Kim (ORCID: https://orcid.org/0000-0003-1404-0575)
- Ayesha Aijaz
- Stephanie Yohay
Institutions
- Medical College of Wisconsin (US)
- Moffitt Cancer Center (US)
- Yale University (US)
Publication Details
- Journal
- British Journal of Haematology
- Published
- 2024-10-13
- DOI
- https://doi.org/10.1111/bjh.19811
- Citations
- 3
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.36
Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- Sanofi
- Spectrum Pharmaceuticals
- Celgene
- Medical College of Wisconsin
- Regeneron Pharmaceuticals
- Prothena
- Janssen Scientific Affairs
- Incyte
- Health Resources and Services Administration
- Genentech
- National Heart, Lung, and Blood Institute
- Office of Naval Research
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases